Last reviewed · How we verify
Intradermal vaccine
Intradermal vaccines deliver immunogenic antigens into the dermis to stimulate local and systemic immune responses with potentially enhanced immunogenicity compared to intramuscular administration.
Intradermal vaccines deliver immunogenic antigens into the dermis to stimulate local and systemic immune responses with potentially enhanced immunogenicity compared to intramuscular administration. Used for Influenza prevention (intradermal formulations), Tuberculosis prevention (BCG and experimental TB vaccines), Other infectious diseases via intradermal route (varies by specific vaccine).
At a glance
| Generic name | Intradermal vaccine |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Intradermal administration targets the dermis, which is rich in antigen-presenting cells and immune effector cells, allowing for more efficient antigen presentation and T-cell activation. This route can reduce the required antigen dose while maintaining or improving immune response, and may enhance both cellular and humoral immunity depending on the vaccine formulation.
Approved indications
- Influenza prevention (intradermal formulations)
- Tuberculosis prevention (BCG and experimental TB vaccines)
- Other infectious diseases via intradermal route (varies by specific vaccine)
Common side effects
- Local injection site reactions (erythema, induration, pruritus)
- Mild systemic symptoms (myalgia, fatigue)
- Headache
- Low-grade fever
Key clinical trials
- Study of AV-1959D, an Amyloid Beta Vaccine (PHASE1)
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age (PHASE1)
- S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer (PHASE3)
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
- Evaluating the Safety and Immunogenicity of MTBVAC (PHASE2)
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intradermal vaccine CI brief — competitive landscape report
- Intradermal vaccine updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI